Highlights

  • The initial Phase 1a cohort completed dosing and follow-up.
  • The safety committee supported progression to Cohort 2.
  • Closing cash was A$2.233m.
  • The disclosed funding runway was 1.78 quarters.
  • An R&D tax refund was expected in the December quarter.

Patrys Limited (ASX:PAB) is a biotechnology company developing a clinical-stage reformulation programme and an antibody technology portfolio. After completion of dosing and follow-up for the first four participants in its RLS-2202 Phase 1a trial, the safety committee recommended progressing to a second cohort. The September 2026 cash report also showed a limited estimated operating runway.

Phase 1a safety assessment

For ASX:PAB, Patrys said human research ethics committee approval for the trial was granted on 27 August 2026. Cohort 1 dosing and follow-up took place at CMAX in Adelaide. Cohort 2 is planned to include 12 participants, and the company is targeting final dosing in the December 2026 quarter. That timing is subject to release of the current good manufacturing practice batch from BioCina, and to screening, enrolment and dosing being completed in the same period.

Deoxymab and research portfolio

In its Deoxymab programme, ASX:PAB Patrys said it has a binding agreement with Yale University under which Patrys is entitled to 50 per cent of the commercialisation revenue Yale receives that is directly attributable to the portfolio. Yale will fund most future development costs. The company noted that this means it gives up direct control of the intellectual property and receives a share of revenue Yale receives rather than the full commercial return. Separately, pre-clinical vasculitis research on the DX1 and DX3 candidates continues in collaboration with Monash University.

Cash flow and financing requirements

Patrys reported no receipts from customers for the quarter. Net operating cash outflow was A$1.252m, made up mainly of research and development spending of A$921,000, administration and corporate costs of A$262,000 and staff costs of A$136,000, partly offset by A$67,000 of interest and other receipts. Financing inflows were A$127,000 net, being A$130,000 of equity proceeds less A$3,000 of transaction costs. Closing cash was A$2.233m, compared with A$3.360m at the end of the previous quarter. Payments to related parties were A$66,458, all non-executive director fees.

The company has no financing facilities, drawn or undrawn. On its Appendix 4C calculation, the estimated runway is 1.78 quarters, below the two-quarter threshold that triggers additional disclosure, so Patrys answered the related questions in the form. It said it expects an R&D tax incentive refund of about A$620,000 in the December 2026 quarter, and that it continues to assess additional funding opportunities, but no further funding has been secured. The company's ability to continue operations therefore depends on that refund and on future capital raisings, neither of which is assured.

Other risks flagged include the dependence of the Cohort 2 timetable on batch release, and the fact that future engagement with regulators, including the United States Food and Drug Administration, is not yet secured.

The trial is an early safety study, and the report describes no efficacy findings, regulatory approval or commercial product. The company has not said how it would fund activity beyond the refund if no further capital is raised.

Patrys said it plans to dose Cohort 2 in the December 2026 quarter, subject to batch release, and expects the R&D refund in the same period. Its annual general meeting is scheduled for 30 November 2026.

For ASX:PAB, an acceptable safety finding in the first cohort allows the study protocol to advance, but it does not demonstrate therapeutic efficacy. The planned next cohort is dependent on manufacturing batch release and participant recruitment. The disclosed funding estimate assumes the reported quarterly spending rate.

Key Insights

The September 2026 disclosures place the development of PAB within a defined set of operational and financing conditions. ASX:PAB has reported specific milestones, but pending approvals, study outcomes or transaction conditions should not be treated as completed events. The reported figures describe the periods and accounting measures identified by the company.